Eledon Pharmaceuticals, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Eledon Pharmaceuticals, Inc. (ELDN) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $4.01 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-03-19
- Eledon Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $4.01, a 80.63% increase from fiscal 2024.
- Eledon Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $2.22, a 5.71% increase from fiscal 2023.
- Eledon Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $2.10, a 44.88% decline from fiscal 2022.
- Eledon Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $3.81, a 64.36% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|
| 2025-12-31 | $4.01 10-K · filed 2026-03-19 | |
| 2024-12-31 | $2.22 10-K · filed 2026-03-19 | |
| 2023-12-31 | $2.10 10-K/A · filed 2025-08-14 | |
| 2022-12-31 | $3.81 10-K/A · filed 2024-08-19 | |
| 2021-12-31 | $10.69 10-K · filed 2023-03-30 | |
| 2020-12-31 | $9.15 10-K · filed 2022-03-24 | |
| 2019-12-31 | $28.87 10-K · filed 2021-03-31 | |
| 2018-12-31 | $5.02 10-K · filed 2019-03-28 | |
| 2017-12-31 | $5.45 10-K · filed 2019-03-28 | $5.54 10-K · filed 2018-04-02 |
| 2016-12-31 | $19.75 10-K · filed 2018-04-02 | $6.17 10-K · filed 2017-03-03 |
| 2015-12-31 | $10.60 10-K · filed 2016-03-10 | |
| 2014-12-31 | $9.77 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |